Prof. Edmond Frémy (1814-1894) - Paris (France)
Prof. Hermann Emil Louis Fischer (1852-1919) - Munich / Erlangen / Wuerzburg / Berlin (Germany)
Prof. Henri Moissan (1852-1907) - Paris (France)
Prof. Anatole Abragam (1914-2011) - CEA Saclay (France)
Prof. Louis Néel (1904-2000) - CEA Grenoble (France)
- Creation of the Scientific Polygon in Grenoble (1956): CENG, ILL, ESRF, etc...
- Creation of a Physical Organic Chemistry laboratory (COP) by 2 young chemists from ENS Paris (France):
* Prof. Didier Gagnaire (1930-2014) - CEA Grenoble (France) / Nuclear Magnetic Resonance (NMR) - Carbohydrates / Founder of CERMAV (1966)
* Prof. André Rassat (1932-2005) - CEA Grenoble (France) / Electron Spin Resonance (ESR) - Nitroxides
Prof. Harden McConnell (1927-2014) - Stanford (USA)
Dr. Francis Cinget (Ph.D. Thesis) - CEA Grenoble (France) / Double Spin Labeling in the D-Glucose Series:
Perturbation of the Spin-Lattice Relaxation Time in 13C and 19F NMR by a Nitroxide Radical - Probe for Intramolecular Distances
Dr. Francis Cinget & Prof. Tomoya Ogawa - RIKEN (Wako, Japan)
Prof. Stephen Fesik - Abbott (USA)
Dr. Francis Cinget - Sumitomo Pharmaceuticals (Osaka, Japan)
1995~ NMR-based Conformational Analysis of Bio-active Oligosaccharides
1997~ NMR-based Fragment-based Drug Design (FBDD)
Dr. Wolfgang Jahnke - Novartis (Basel, Switzerland)
Dr. Claudio Dalvit - Nerviano Medical Sciences (Milano, Italy)
FDA Approval of Vemurafenib / B-Raf (Plexxikon / Roche)
FDA Approval of Venetoclax / Selective Bcl-2 (AbbVie)
1976~ started Laboratory Sciences: Physics, Chemistry, Biology (Reims - France)
1982~ started Materials Sciences (Prof. Jean Rouxel - Nantes, France / Founder of IMN - 1988)
1983~ started NMR (Prof. Maryvonne L. Martin - Nantes, France / Co-founder of Eurofins Scientific - 1987)
1986~ started Carbohydrates (Prof. Jacques Gelas - Clermont-Ferrand, France)
1995~ started NMR-based Drug Design (Sumitomo Pharmaceuticals - Osaka, Japan)
2005~ founded Scientifically Driven Platform (SynphaTec Japon Co., Ltd. - Osaka, Japan)
Ultra-fast Fragment-based Theranostic Design, Discovery and Development (UF-FBT3D)
Explore, develop and apply our robust resonance-based strategies and new magic fragment collection to tackle key therapeutic targets of interest and help our customers to discover new drugs faster, at a lower cost and more efficiently. In parallel to this, our efforts are continuously directed towards the development of personalized medicine.
Bridging Smart R&D Services Worldwide
Build-up a multi-disciplinary portfolio of products and services based on external expertise and know-how to complement our internal scientific background, expertise and know-how.
Create, develop, optimize and harmonize synergies between disruptive internal and external innovations (science, technology, expertise and know-how) to support our customers in a unique manner.
Design, set-up and launch new R&D projects to strengthen scientific collaborations between Europe and the Asia-Pacific region, especially in the global fields of Life Sciences and Materials Sciences.
Ministry of Health, Labour & Welfare / Hospitals / Research Institutes / University Laboratories / CRDMOs / Trading Companies / Global Companies:
Pharmaceutical / Medical / Nutraceutical / Cosmeceutical / Veterinary / Agrochemical / Chemical
Biotech / Medtech / Chemtech / Materials / Electronic / Energy / Environment